At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
TSHA Taysha Gene Therapies, Inc.
Post-Mkt 11-04 19:00:13 EST
4.36
+0.27
+6.60%
盘后4.36
+0.000.00%
18:53 EST
High4.38Low4.01Vol4.03M
Open4.08D1 Closing4.09Amplitude9.17%
Mkt Cap1.42BTradable Cap1.02BTotal Shares325.83M
T/O17.24MT/O Rate1.73%Tradable Shares233.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Taysha Gene Therapies (TSHA) After Early Rett Data With An Undervalued Narrative
Simply Wall St.  ·  10-20
Taysha Gene Therapies (TSHA) After Early Rett Data With An Undervalued Narrative
Does Rett Trial Progress Change The Bull Case For Taysha Gene Therapies Stock?
Simply Wall St.  ·  10-19
Does Rett Trial Progress Change The Bull Case For Taysha Gene Therapies Stock?
Taysha Gene Therapies Grants New Hires 384,000 RSUs, Options for 92,400 Shares Under Inducement Plan
Reuters  ·  10-02
Taysha Gene Therapies Grants New Hires 384,000 RSUs, Options for 92,400 Shares Under Inducement Plan
Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  10-02
Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  10-02
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Highlights Phase 1/2 Reveal Trial Data for TSHA-102 in Rett Syndrome at Child Neurology Society Meeting
Reuters  ·  10-01
Taysha Gene Therapies Highlights Phase 1/2 Reveal Trial Data for TSHA-102 in Rett Syndrome at Child Neurology Society Meeting
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting Tsha-102 Rett Syndrome Clinical Program at the 55TH Child Neurology Society Annual Meeting
THOMSON REUTERS  ·  10-01
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting Tsha-102 Rett Syndrome Clinical Program at the 55TH Child Neurology Society Annual Meeting
Wolfe Research Initiates Taysha Gene Therapies at Outperform
MT Newswires Live  ·  09-17
Wolfe Research Initiates Taysha Gene Therapies at Outperform
Taysha Gene Therapies initiated with an Outperform at Wolfe Research
TIPRANKS  ·  09-17
Taysha Gene Therapies initiated with an Outperform at Wolfe Research
Taysha Gene Therapies Grants New Hires 314,000 RSUs, 92,400 Options at $5.7 Strike
Reuters  ·  09-04
Taysha Gene Therapies Grants New Hires 314,000 RSUs, 92,400 Options at $5.7 Strike
Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  09-04
Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  09-04
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies Highlights TSHA-102 Rett Gene Therapy Path Toward BLA Submission in Corporate Presentation
Reuters  ·  09-01
Taysha Gene Therapies Highlights TSHA-102 Rett Gene Therapy Path Toward BLA Submission in Corporate Presentation
MeiraGTx Q2 Revenue Jumps on Reogen License Revenue
Reuters  ·  08-13
MeiraGTx Q2 Revenue Jumps on Reogen License Revenue
Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations
Reuters  ·  08-13
Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations
Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return
Simply Wall St.  ·  08-13
Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return
Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs
Reuters  ·  08-13
Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Reuters  ·  08-13
U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
TIPRANKS  ·  08-12
Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  08-12
Wall Street Analysts Are Bullish on Top Healthcare Picks

Introduction

Company Name.
Taysha Gene Therapies, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Issue price:
--